Monika Lipa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Monika Lipa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Tomasz Skóra
Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland
3 shared publications - Antoni Rucinski
Institute of Nuclear Physics PAS, Radzikowskiego 152, Krakow, 31-342, POLAND
2 shared publications - Dawid Krzempek
Institute of Nuclear Physics Polish Academy of Sciences, Krakow, PL-31342, Poland
2 shared publications - Gabriela Foltyńska
Institute of Nuclear Physics Polish Academy of Sciences, Radzikowskiego 152, Krakow, 31-342, Poland
2 shared publications - Jan Gajewski
Institute of Nuclear Physics PAN, Kraków, Poland
2 shared publications - Magdalena Garbacz
Institute of Nuclear Physics Polish Academy of Sciences, 31-342 Kraków, Poland
2 shared publications
Latest Publications
- 6 January 2026
- Published by Elsevier in Physica Medica
- Vol. 142, 105718
Validation of the Tena pregnancy phantom and fetal dose assessment in proton scanning beam therapy
- 6 January 2026
- Published by Elsevier in Physica Medica
- Vol. 142, 105718
Validation of the Tena pregnancy phantom and fetal dose assessment in proton scanning beam therapy
- Open Access
- 14 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (14) , 145011
Fast Monte Carlo log-based framework for robust 4D dose evaluation in proton therapy
Objective. Cyclotron Centre Bronowice Krakow proton therapy center is establishing a methodology for dosimetric evaluation to support treatments of moving targets, particularly in the mediastinal area. We propose a robust 4D Monte Carlo (MC) dose evaluation approach for proton treatment plans, integrating temporal information on both pencil beam delivery and organ motion in the context of free-breathing treatments. Approach. A specialized tool combining the GPU-accelerated FRED MC code and temporal patient and treatment delivery data was developed. The methodology includes standard 3D dose evaluation for setup and CT calibration uncertainties, plan recalculation across respiratory phases, and robust 4D dose evaluation (4DDE). The 4DDE approach accumulates dose over deformable respiratory phases using log file time information to assess treatment plans at various respiratory cycle starting points. Validation used anonymized 4D computed tomography scans from a Hodgkin lymphoma patient, with deformable image registration extracting motion vector fields. For reference, proton plans were also recalculated on the median tumor position phase image and results were analyzed for dose–volume histograms parameters variability, 3D gamma index (GI) analysis (3%/3 mm) and voxel-wise worst case scenario, relative to the reference treatment planning system calculation. Main results. Exemplary robust 4DDE revealed that considering time provides insight into the worst-case scenarios, resulting in wider dose ranges (GI 55.05% to 88.36% vs 48.26% to 92.92% for 3D and 4D analysis, respectively). The voxel-wise worst-case dose distribution showed reduced target coverage by 47.4% and 20.8% (for 95% and 90% isodose) when accounting for respiratory motion. Significance. The study introduces a fast tool for 4DDE, demonstrating versatility ensures robustness in 3D and 4D evaluations, underscoring the significance of dynamic anatomical considerations in 4D proton radiotherapy.
- 14 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (14) , 145011
Open AccessFast Monte Carlo log-based framework for robust 4D dose evaluation in proton therapy
Objective. Cyclotron Centre Bronowice Krakow proton therapy center is establishing a methodology for dosimetric evaluation to support treatments of moving targets, particularly in the mediastinal area. We propose a robust 4D Monte Carlo (MC) dose evaluation approach for proton treatment plans, integrating temporal information on both pencil beam delivery and organ motion in the context of free-breathing treatments. Approach. A specialized tool combining the GPU-accelerated FRED MC code and temporal patient and treatment delivery data was developed. The methodology includes standard 3D dose evaluation for setup and CT calibration uncertainties, plan recalculation across respiratory phases, and robust 4D dose evaluation (4DDE). The 4DDE approach accumulates dose over deformable respiratory phases using log file time information to assess treatment plans at various respiratory cycle starting points. Validation used anonymized 4D computed tomography scans from a Hodgkin lymphoma patient, with deformable image registration extracting motion vector fields. For reference, proton plans were also recalculated on the median tumor position phase image and results were analyzed for dose–volume histograms parameters variability, 3D gamma index (GI) analysis (3%/3 mm) and voxel-wise worst case scenario, relative to the reference treatment planning system calculation. Main results. Exemplary robust 4DDE revealed that considering time provides insight into the worst-case scenarios, resulting in wider dose ranges (GI 55.05% to 88.36% vs 48.26% to 92.92% for 3D and 4D analysis, respectively). The voxel-wise worst-case dose distribution showed reduced target coverage by 47.4% and 20.8% (for 95% and 90% isodose) when accounting for respiratory motion. Significance. The study introduces a fast tool for 4DDE, demonstrating versatility ensures robustness in 3D and 4D evaluations, underscoring the significance of dynamic anatomical considerations in 4D proton radiotherapy.
- Open Access
Proton Therapy Adaptation of Perisinusoidal and Brain Areas in the Cyclotron Centre Bronowice in Krakow: A Dosimetric Analysis
Applying a proton beam in radiotherapy enables precise irradiation of the tumor volume, but only for continuous assessment of changes in patient anatomy. Proton beam range uncertainties in the treatment process may originate not only from physical beam properties but also from patient-specific factors such as tumor shrinkage, edema formation and sinus filling, which are not incorporated in tumor volume safety margins. In this paper, we evaluated variations in dose distribution in proton therapy resulting from the differences observed in the control tomographic images and the dosimetric influence of applied adaptive treatment. The data from weekly computed tomography (CT) control scans of 21 patients, which serve as the basis for adaptive radiotherapy, were used for this study. Dosimetric analysis of adaptive proton therapy (APT) was performed on patients with head and neck (H&N) area tumors who were divided into two groups: patients with tumors in the sinus/nasal area and patients with tumors in the brain area. For this analysis, the reference treatment plans were forward-calculated using weekly control CT scans. A comparative evaluation of organ at risk (OAR) dose-volume histogram (DVH) parameters, as well as conformity and homogeneity indices, was conducted between the initial and recalculated dose distributions to assess the necessity of the adaptation process in terms of dosimetric parameters. Changes in PTV volume after replanning were observed in seventeen patient cases, showing a discrepancy of over 1 in ten cases. In these cases, tumor progression occurred in 30% of patients, while regression was observed in 70%. The statistical analysis indicates that the use of the adaptive planning procedure results in a statistically significant improvement in dose distribution, particularly in the PTV area. The findings led to the conclusion that the adaptive procedure provides significant advantages in terms of dose distribution within the treated volume. However, when considering the entire patient group, APT did not result in a statistically significant dose reduction in OARs ( = 0.05).Open AccessProton Therapy Adaptation of Perisinusoidal and Brain Areas in the Cyclotron Centre Bronowice in Krakow: A Dosimetric Analysis
Applying a proton beam in radiotherapy enables precise irradiation of the tumor volume, but only for continuous assessment of changes in patient anatomy. Proton beam range uncertainties in the treatment process may originate not only from physical beam properties but also from patient-specific factors such as tumor shrinkage, edema formation and sinus filling, which are not incorporated in tumor volume safety margins. In this paper, we evaluated variations in dose distribution in proton therapy resulting from the differences observed in the control tomographic images and the dosimetric influence of applied adaptive treatment. The data from weekly computed tomography (CT) control scans of 21 patients, which serve as the basis for adaptive radiotherapy, were used for this study. Dosimetric analysis of adaptive proton therapy (APT) was performed on patients with head and neck (H&N) area tumors who were divided into two groups: patients with tumors in the sinus/nasal area and patients with tumors in the brain area. For this analysis, the reference treatment plans were forward-calculated using weekly control CT scans. A comparative evaluation of organ at risk (OAR) dose-volume histogram (DVH) parameters, as well as conformity and homogeneity indices, was conducted between the initial and recalculated dose distributions to assess the necessity of the adaptation process in terms of dosimetric parameters. Changes in PTV volume after replanning were observed in seventeen patient cases, showing a discrepancy of over 1 in ten cases. In these cases, tumor progression occurred in 30% of patients, while regression was observed in 70%. The statistical analysis indicates that the use of the adaptive planning procedure results in a statistically significant improvement in dose distribution, particularly in the PTV area. The findings led to the conclusion that the adaptive procedure provides significant advantages in terms of dose distribution within the treated volume. However, when considering the entire patient group, APT did not result in a statistically significant dose reduction in OARs ( = 0.05).